NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's Disease [Yahoo! Finance]
NeuroSense Therapeutics Ltd. (NRSN)
Company Research
Source: Yahoo! Finance
for severe neurodegenerative diseases announced today a collaboration in Alzheimer's Disease (AD) drug development with Genetika+ , a leader in precision medicine for psychiatry and neurology. The multi-phase collaboration, which will commence in NeuroSense's currently ongoing Phase 2 AD clinical trial, leverages Genetika+'s state-of-the-art technology that derives frontal cortex neurons from individual patients' blood to quantify drug-induced neuronal plasticity in vitro The Genetika+ technology serves as a human AD disease model and will be used to correlate clinical response with cellular effects, for mechanistic drug insights and patient subset identification, supporting drug development and potentially commercialization. This collaboration addresses key challenges in the development of drugs for AD, by promoting disease and drug mechanistic understanding, increasing the likelihood of success of AD drug development, and enabling the realization of precision medicine approaches.
Show less
Read more
Impact Snapshot
Event Time:
NRSN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NRSN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NRSN alerts
High impacting NeuroSense Therapeutics Ltd. news events
Weekly update
A roundup of the hottest topics
NRSN
News
- NeuroSense Announces First Quarter 2024 Business Update [Yahoo! Finance]Yahoo! Finance
- NeuroSense Announces First Quarter 2024 Business UpdatePR Newswire
- NeuroSense and Genetika+ Initiate Precision Medicine Collaboration Beginning with Ongoing Phase 2 Clinical Trial in Alzheimer's DiseasePR Newswire
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- NeuroSense Presents Positive Data Validating Phase 2b Topline Readout During Emerging Science Presentation at the American Academy of Neurology Annual MeetingPR Newswire
NRSN
Sec Filings
- 4/25/24 - Form D
- 4/12/24 - Form 424B5
- 4/12/24 - Form 6-K
- NRSN's page on the SEC website